Back to News
Market Impact: 0.4
NeurAxis Expands PENFS Coverage By 18 Million Lives As IB-Stim Adoption Grows; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
NeurAxis secured expanded national health-insurer coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, extending potential access to approximately 18 million additional members. The coverage milestone could materially broaden the addressable reimbursed market for the company’s therapy and support future utilization growth.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
NRXS0.75
More News
- Why Wendy’s is losing the burger wars—and is now a takeover target for Nelson Peltz
- Companies promised AI gains— here's how the payoff showed up in earnings
- FBI blames North Korea for record $6.3bn crypto heist
- Binance to resume crypto withdrawals in phases after record $6 billion hack
- AWS grows 39% and Amazon will spend even more on AI in 2027
- SpaceX loses bid to toss NAACP lawsuit over Memphis data center air pollution